CIK 0000730272
- Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 042729386
- Phone
- +1 781-449-9560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- 4 Shares withheld for taxes Chief Executive Officer gave up 3,273 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Financial Officer gave up 682 shares (to pay taxes)
- 4 Shares withheld for taxes Senior VP, R&D gave up 458 shares (to pay taxes)
- 4 Shares withheld for taxes See Remarks gave up 452 shares (to pay taxes)
- 4 Open-market sale Chief Financial Officer sold 5,647 shares at $200.00 ($1,129,400)
- 4 Grant or award Director acquired 111 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 625 shares at $175.02 ($109,388)
- 4 Open-market sale Chief Executive Officer sold 25,000 shares at $200.00 ($5,000,000)
- 4 Option exercise Chief Financial Officer acquired 466 shares (option exercise)
- 4 Open-market sale Director sold 775 shares at $227.17 ($176,057)
- 4 Open-market sale Chief Executive Officer sold 26,402 shares at an average $224.73 ($5,933,438)
- 4 Open-market sale Chief Financial Officer sold 6,698 shares at an average $252.86 ($1,693,689)
- 4 Open-market sale Senior VP, R&D sold 4,840 shares at an average $254.32 ($1,230,886)
- 4 Open-market sale See Remarks sold 3,357 shares at $243.01 ($815,785)
- 4 Open-market sale Chief Operating Officer sold 2,000 shares at $240.40 ($480,800)
- 4 Open-market sale Chief Financial Officer sold 2,000 shares at $220.00 ($440,000)
- 4 Open-market sale Chief Executive Officer sold 24,802 shares at $200.00 ($4,960,400)
- 4 Grant or award Director acquired 1,202 shares (grant or award)
- 4 Grant or award Director acquired 534 shares (grant or award)
Page 9 of 34 · 669 filings